Literature DB >> 31803804

Comparative evaluation of three rapid immunochromatographic test assays with chemiluminescent microparticle immunoassay for the detection of hepatitis C virus antibody.

Supriya Mahajan1, Reshu Agarwal1, Vaishali Rawat1, Guresh Kumar2, Manoj Kumar Sharma3, Ekta Gupta1.   

Abstract

Rapid diagnostic tests (RDTs) can serve as good alternatives to standard serological assays for hepatitis C virus (HCV) detection in limited resource settings. Aim of this study was to evaluate performance of three Indian manufactured RDTs with chemiluminescent microparticle immunoassay (CLIA) for screening of HCV infection with further evaluation using HCV RNA. Serum samples tested for anti-HCV by CLIA (Architect i1000SR, Abbott Diagnostics, IL, USA) were retrieved from - 80 °C and retested for anti-HCV by three RDTs: Alere Trueline (SD Bioline; Haryana, India) (RDT 1), Benesphera HCV Rapid card test (Avantor Performance Materials India Limited; Uttarakhand, India) (RDT 2), AccuTest HCV (Accurex Biomedical Pvt. Ltd.; Mumbai, India) (RDT 3). HCV RNA results were obtained from hospital information system and anti-HCV reactive but RNA negative cases without treatment were considered as either 'false positives' or 'spontaneous clearance of HCV RNA'. Among 86 samples, 75 (87.2%), 49 (57%), 58 (67.4%) and 51 (59.3%) were reactive by CLIA, RDT1, RDT2 and RDT3, respectively. Taking CLIA as reference standard, RDT 1, 2 and 3 demonstrated sensitivity of 65.30%, 77.33% and 68% respectively. Specificity of all three RDTs was 100% with sensitivity of 97.6-100% above signal/cut-off ratio (S/Co) of 6 by CLIA and 88-100% in all HCV RNA positive cases. Sensitivity of RDTs increased from 65.30-77.33 to 72-82.4% when RNA negative/anti-HCV reactive results were considered as non-reactive. The three RDTs have acceptable sensitivity and specificity in anti-HCV detection especially in RNA positive patients that would require treatment for HCV. © Indian Virological Society 2019.

Entities:  

Keywords:  Anti-HCV; Chemiluminescent microparticle immunoassay; HCV RNA; Hepatitis C virus; Rapid diagnostic tests

Year:  2019        PMID: 31803804      PMCID: PMC6864144          DOI: 10.1007/s13337-019-00542-5

Source DB:  PubMed          Journal:  Virusdisease        ISSN: 2347-3584


  29 in total

1.  A rapid test for the visual detection of anti-hepatitis C virus antibodies in whole blood.

Authors:  L Montebugnoli; G Borea; R Miniero; G Sprovieri
Journal:  Clin Chim Acta       Date:  1999-10       Impact factor: 3.786

2.  Evaluation of anew rapid whole-blood serological test for hepatitis c virus.

Authors:  A Y Hui; F K L Chan; P K S Chan; J S L Tam; J J Y Sung
Journal:  Acta Virol       Date:  2002       Impact factor: 1.162

3.  Impact of changes in viral marker screening assays.

Authors:  Usha K Sharma; Susan L Stramer; David J Wright; Simone A Glynn; Sigurd Hermansen; George B Schreiber; Steven H Kleinman; Michael P Busch
Journal:  Transfusion       Date:  2003-02       Impact factor: 3.157

Review 4.  Economic Evidence and Point-of-Care Testing.

Authors:  Andrew St John; Christopher P Price
Journal:  Clin Biochem Rev       Date:  2013-08

5.  Rapid method for the detection of anti-HCV antibodies in patients with chronic hepatitis C.

Authors:  M Buti; M Cotrina; H Chan; R Jardí; F Rodríguez; X Costa; R Esteban; J Guàrdia
Journal:  Rev Esp Enferm Dig       Date:  2000-03       Impact factor: 2.086

6.  Evaluation and comparison of three different anti-hepatitis C virus antibody tests based on chemiluminescence and enzyme-linked immunosorbent assay methods used in the diagnosis of hepatitis C infections in Turkey.

Authors:  Recep Kesli; M Ozdemir; M G Kurtoglu; M Baykan; B Baysal
Journal:  J Int Med Res       Date:  2009 Sep-Oct       Impact factor: 1.671

7.  Field-based performance of three pre-market rapid hepatitis C virus antibody assays in STAHR (Study to Assess Hepatitis C Risk) among young adults who inject drugs in San Diego, CA.

Authors:  A Jewett; B D Smith; R S Garfein; J Cuevas-Mota; E H Teshale; C M Weinbaum
Journal:  J Clin Virol       Date:  2012-05-03       Impact factor: 3.168

8.  Sensitivity and specificity of point-of-care rapid combination syphilis-HIV-HCV tests.

Authors:  Kristen L Hess; Dennis G Fisher; Grace L Reynolds
Journal:  PLoS One       Date:  2014-11-06       Impact factor: 3.240

9.  Performance evaluation of the OraQuick hepatitis C virus rapid antibody test.

Authors:  Young Joo Cha; Quehn Park; Eun-Suk Kang; Byung Chul Yoo; Kyoung Un Park; Jin-Wook Kim; Yoo-Sung Hwang; Myung Hee Kim
Journal:  Ann Lab Med       Date:  2013-04-17       Impact factor: 3.464

10.  Diagnostic Performance of Two Point-of-Care Tests for Anti-HCV Detection.

Authors:  Lígia da Rosa; Esther Buzaglo Dantas-Corrêa; Janaína Luz Narciso-Schiavon; Leonardo de Lucca Schiavon
Journal:  Hepat Mon       Date:  2013-09-10       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.